(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are OSE IMMUNO, SAS AB, and ELLIPTIC LABORATOR.

Financial Asset	Price	Change	Updated (EST)
OSE IMMUNO (OSE.PA)	4.92	48.71%	2024-02-28 13:21:04
SAS AB (SASNO.OL)	0.04	45.35%	2024-02-28 12:42:49
ELLIPTIC LABORATOR (ELABS.OL)	14.14	11.51%	2024-02-28 12:25:52
LERØY SEAFOOD GP (LSG.OL)	44.30	10.75%	2024-02-28 12:41:03
AUSTEVOLL SEAFOOD (AUSS.OL)	79.65	9.71%	2024-02-28 12:24:53
PCI BIOTECH HOLD (PCIB.OL)	1.92	9.71%	2024-02-28 12:42:10
NORTHERN OCEAN LTD (NOL.OL)	8.76	7.62%	2024-02-28 12:41:39
POLIGHT (PLT.OL)	7.52	7.43%	2024-02-28 12:42:23
INTERPARFUMS (ITP.PA)	53.30	7.24%	2024-02-28 13:05:25
NEL (NEL.OL)	4.89	7.12%	2024-02-28 12:41:25

The three biggest losers today are AB SCIENCE, FERMENTALG, and CASINO GUICHARD.

Financial Asset	Price	Change	Updated (EST)
AB SCIENCE (AB.PA)	1.62	-25.35%	2024-02-28 12:44:38
FERMENTALG (FALG.PA)	0.49	-24.92%	2024-02-28 13:03:37
CASINO GUICHARD (CO.PA)	0.56	-20.93%	2024-02-28 13:01:03
TELEPERFORMANCE (TEP.PA)	111.80	-16.13%	2024-02-28 13:23:34
ONWARD MEDICAL (ONWD.BR)	4.55	-10.78%	2024-02-28 12:20:58
MYHOTELMATCH (MHM.PA)	0.72	-10.27%	2024-02-28 13:20:29
MAAT PHARMA (MAAT.PA)	7.66	-9.88%	2024-02-28 13:06:21
AVENIR TELECOM (AVT.PA)	0.13	-9.18%	2024-02-28 12:46:10
ENSURGE MICROPOWER (ENSU.OL)	0.30	-8.72%	2024-02-28 12:25:59
GROUPE JAJ (GJAJ.PA)	1.10	-8.33%	2024-02-28 13:04:46

Winners today

1. OSE IMMUNO (OSE.PA)

48.71% Price Change

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

CAC 40 ended the session with OSE IMMUNO jumping 48.71% to €4.92 on Wednesday while CAC 40 rose 0.08% to €7,954.39.

Earnings Per Share

As for profitability, OSE IMMUNO has a trailing twelve months EPS of €-0.4.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -79.74%.

Volume

Today’s last reported volume for OSE IMMUNO is 1263750 which is 1964.34% above its average volume of 61218.

Volatility

OSE IMMUNO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.30%, a negative 0.80%, and a positive 2.13%.

OSE IMMUNO’s highest amplitude of average volatility was 1.94% (last week), 2.22% (last month), and 2.13% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 91.5%, now sitting on 3.61M for the twelve trailing months.

More news about OSE IMMUNO.

2. SAS AB (SASNO.OL)

45.35% Price Change

SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 134 aircraft, including 16 long-haul aircraft, 87 short-haul aircraft, and 31 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Oslo Børs Benchmark Index_GI ended the session with SAS AB rising 45.35% to €0.04 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, SAS AB has a trailing twelve months EPS of kr-0.8.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SAS AB’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 42.04B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SAS AB’s EBITDA is -389.12.

More news about SAS AB.

3. ELLIPTIC LABORATOR (ELABS.OL)

11.51% Price Change

Elliptic Laboratories ASA, an artificial intelligence (AI) software company, provides AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive industries in Norway, China, Taiwan, South Korea, the United States, and Japan. The company offers AI Virtual human Presence Sensor, a presence-detection solution used to improve the security of data stored on laptops ; AI Virtual Proximity Sensor that enables exquisite full-screen devices; AI Virtual Connection Sensor that allows to pair and authenticate smart devices in the same room; AI Virtual Position Sensor that automatically detects the location of an external display; AI Virtual Gesture Sensor, a touch-free ultrasound gesture technology; AI Virtual Breathing sensor that enables to track person breathing; and AI Virtual heart Sensor that tracks a person's heart rate. Elliptic Laboratories ASA was incorporated in 2006 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ELLIPTIC LABORATOR jumping 11.51% to €14.14 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, ELLIPTIC LABORATOR has a trailing twelve months EPS of kr-0.35.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.11%.

Yearly Top and Bottom Value

ELLIPTIC LABORATOR’s stock is valued at kr14.14 at 21:40 EST, way under its 52-week high of kr24.30 and way higher than its 52-week low of kr10.22.

More news about ELLIPTIC LABORATOR.

4. LERØY SEAFOOD GP (LSG.OL)

10.75% Price Change

Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. It operates in three segments: Wildcatch; Farming; and Value-Added Processing, Sales and Distribution. The company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. Lerøy Seafood Group ASA markets its products primarily under the Norway Seafoods, Arctic Supreme, Fjord trout, Aurora Salmon, Fossen, Sea Eagle, Lerøy, and M?r brands to shops, restaurants, canteens, and hotels. The company was founded in 1899 and is headquartered in Bergen, Norway. Lerøy Seafood Group ASA is a subsidiary of Austevoll Seafood ASA.

Oslo Børs Benchmark Index_GI ended the session with LERØY SEAFOOD GP jumping 10.75% to €44.30 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.3% to €1,263.82, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, LERØY SEAFOOD GP has a trailing twelve months EPS of kr-0.59.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.58%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 29.76B for the twelve trailing months.

Sales Growth

LERØY SEAFOOD GP’s sales growth is 4.6% for the ongoing quarter and negative 7.6% for the next.

More news about LERØY SEAFOOD GP.

5. AUSTEVOLL SEAFOOD (AUSS.OL)

9.71% Price Change

Austevoll Seafood ASA, a seafood company, engages in the salmon and trout, white fish, and pelagic businesses in Norway, the European Union, the United Kingdom, Eastern Europe, Africa, North America, Asia, South America, and internationally. The company is involved in the ownership and operation of fishing vessels, as well as farming, aquaculture, processing, sale, and distribution of salmon and trout. It also produces white fish products, freezing and canning plants, fish meals, and fish oils; omega-3 oil; and canned and frozen fish products. The company was incorporated in 1981 and is headquartered in Storebø, Norway. Austevoll Seafood ASA is a subsidiary of Laco AS.

Oslo Børs Benchmark Index_GI ended the session with AUSTEVOLL SEAFOOD rising 9.71% to €79.65 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, AUSTEVOLL SEAFOOD has a trailing twelve months EPS of kr0.78.

PE Ratio

AUSTEVOLL SEAFOOD has a trailing twelve months price to earnings ratio of 102.12. Meaning, the purchaser of the share is investing kr102.12 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.89%.

More news about AUSTEVOLL SEAFOOD.

6. PCI BIOTECH HOLD (PCIB.OL)

9.71% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD rising 9.71% to €1.92 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

PCI BIOTECH HOLD’s stock is valued at kr1.92 at 21:40 EST, way below its 52-week high of kr3.40 and way higher than its 52-week low of kr1.20.

More news about PCI BIOTECH HOLD.

7. NORTHERN OCEAN LTD (NOL.OL)

7.62% Price Change

Northern Ocean Ltd., a drilling contractor, provides offshore contract drilling services for the oil and gas industry worldwide. The company was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN OCEAN LTD jumping 7.62% to €8.76 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, NORTHERN OCEAN LTD has a trailing twelve months EPS of kr-4.43.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.86%.

More news about NORTHERN OCEAN LTD.

8. POLIGHT (PLT.OL)

7.43% Price Change

poLight ASA develops optical lens for consumer devices and industrial applications in Europe, Asia, and the United States. The company's lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes TLens, a tuneable optical lens for autofocus camera applications; Packaged TLens that facilitates integration of a TLens on a fixed-focus camera module; ASIC drivers, which control the supply of variable voltage to Tlens products and makes them to change focus; TLens Silver and TLens Silver Premium devices; and evaluation kits that allows to test and evaluate the optical and electrical performance of the TLens in new products and/or applications. it serves smartphones and wearables, barcode/industrial, augmented reality, medical endoscopy, webcams, and other markets. poLight ASA was founded in 2005 and is headquartered in Skoppum, Norway.

Oslo Børs Benchmark Index_GI ended the session with POLIGHT jumping 7.43% to €7.52 on Wednesday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.3% to €1,263.82, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.27%.

More news about POLIGHT.

9. INTERPARFUMS (ITP.PA)

7.24% Price Change

Interparfums SA designs, manufactures, and distributes perfumes through license agreements with ready-to-wear, jewelry, or accessories houses in France and internationally. The company operates through Perfumes and Fashion segments. It serves customers under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Montblanc, Moncler, Rochas, S.T. Dupont, Van Cleef & Arpels, and other brand names. The company distributes its products through wholly owned distribution subsidiaries or joint ventures, independent companies, subsidiaries of luxury good corporations, and duty-free operators. Interparfums SA was founded in 1982 and is headquartered in Paris, France. Interparfums SA is a subsidiary of Interparfums Holding SA.

CAC 40 ended the session with INTERPARFUMS jumping 7.24% to €53.30 on Wednesday while CAC 40 rose 0.08% to €7,954.39.

Earnings Per Share

As for profitability, INTERPARFUMS has a trailing twelve months EPS of €1.8.

PE Ratio

INTERPARFUMS has a trailing twelve months price to earnings ratio of 29.61. Meaning, the purchaser of the share is investing €29.61 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.46%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 11, 2023, the estimated forward annual dividend rate is 0.95 and the estimated forward annual dividend yield is 2.26%.

Volume

Today’s last reported volume for INTERPARFUMS is 109464 which is 241.61% above its average volume of 32043.

Moving Average

INTERPARFUMS’s worth is above its 50-day moving average of €52.84 and way below its 200-day moving average of €59.27.

More news about INTERPARFUMS.

10. NEL (NEL.OL)

7.12% Price Change

Nel ASA, a hydrogen company, provides various solutions to produce, store, and distribute hydrogen from renewable energy in Norway and internationally. The company operates in two segments, Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment produces H2Station hydrogen fueling stations that provide fuel cell electric vehicles with the fueling and long range as conventional fossil fuel vehicles, include cars, buses, trucks, and other applications. The Nel Hydrogen Electrolyser segment supplies hydrogen production equipment based on alkaline and proton exchange membrane water electrolysis technology. It serves industry, energy, and gas companies. The company was formerly known as DiaGenic ASA and changed its name to Nel ASA in October 2014. Nel ASA was founded in 1927 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with NEL jumping 7.12% to €4.89 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82.

Earnings Per Share

As for profitability, NEL has a trailing twelve months EPS of kr-0.93.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.62%.

Moving Average

NEL’s value is way under its 50-day moving average of kr5.75 and way below its 200-day moving average of kr9.42.

Volatility

NEL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.21%, a negative 0.68%, and a positive 2.96%.

NEL’s highest amplitude of average volatility was 2.99% (last week), 2.27% (last month), and 2.96% (last quarter).

More news about NEL.

Losers Today

1. AB SCIENCE (AB.PA)

-25.35% Price Change

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

CAC 40 ended the session with AB SCIENCE dropping 25.35% to €1.62 on Wednesday while CAC 40 jumped 0.08% to €7,954.39.

Earnings Per Share

As for profitability, AB SCIENCE has a trailing twelve months EPS of €-0.36.

Volume

Today’s last reported volume for AB SCIENCE is 799966 which is 491.94% above its average volume of 135143.

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.8%, now sitting on 777k for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AB SCIENCE’s stock is considered to be overbought (>=80).

More news about AB SCIENCE.

2. FERMENTALG (FALG.PA)

-24.92% Price Change

Fermentalg SA develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in France and internationally. It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate dedicated to aquafeed applications; Everzure, an extract of natural acid stable blue color; BLUE ORIGINS AOX, an antioxidant and anti-inflammatory activities; BLUE ORIGIN, a natural color; and environmental and clean air solutions that captures CO2 in industries. The company was incorporated in 2009 and is headquartered in Libourne, France.

CAC 40 ended the session with FERMENTALG falling 24.92% to €0.49 on Wednesday, after two sequential sessions in a row of losses. CAC 40 jumped 0.08% to €7,954.39, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, FERMENTALG has a trailing twelve months EPS of €-0.24.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.52%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 55.4%, now sitting on 4.75M for the twelve trailing months.

Moving Average

FERMENTALG’s worth is under its 50-day moving average of €0.50 and way under its 200-day moving average of €0.90.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FERMENTALG’s stock is considered to be overbought (>=80).

More news about FERMENTALG.

3. CASINO GUICHARD (CO.PA)

-20.93% Price Change

Casino, Guichard-Perrachon S.A. operates as a food retailer in France, Latin America, and internationally. The company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. It also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. It operates through stores. The company was founded in 1898 and is based in Saint-Étienne, France.Casino, Guichard-Perrachon S.A operates as a subsidiary of Rallye SA.

CAC 40 ended the session with CASINO GUICHARD falling 20.93% to €0.56 on Wednesday while CAC 40 rose 0.08% to €7,954.39.

Earnings Per Share

As for profitability, CASINO GUICHARD has a trailing twelve months EPS of €-20.53.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.71%.

Sales Growth

CASINO GUICHARD’s sales growth for the next quarter is negative 11.2%.

Volume

Today’s last reported volume for CASINO GUICHARD is 1899640 which is 101.51% above its average volume of 942678.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5%, now sitting on 33.42B for the twelve trailing months.

Yearly Top and Bottom Value

CASINO GUICHARD’s stock is valued at €0.56 at 21:40 EST, way below its 52-week high of €10.14 and way above its 52-week low of €0.38.

More news about CASINO GUICHARD.

4. TELEPERFORMANCE (TEP.PA)

-16.13% Price Change

Teleperformance SE, together with its subsidiaries, engages in the provision of outsourced customer and citizen experience management, and related services in France and internationally. The company operates in two segments, Core Services and Digital Integrated Business Services, and Specialized Services. The Core Services and Digital Integrated Business Services segment offers customer and citizen care; customer relationship operations; technical support; and technical assistance and customer acquisition services, as well as back-office solutions and integrated services, including social media content moderation services and data labeling for automation solutions; and knowledge services in the field of analytics solutions, automated systems, and artificial intelligence. The company also manages business processes, as well as provides digital platform, consulting, and data analysis services; and business process outsourcing services for government agencies. The Specialized Services segment provides on-line interpretation, visa application management, health management services, and accounts receivable credit management services. It also offers digital recruitment process outsourcing; consumer health management business services and related digital solutions integration; translation and interpreting services; and business process outsourcing services for government agencies in the United States. The company serves automotive, energy and utilities, insurance, public sector, technology, travel and hospitality, and banking and financial services, as well as healthcare, media, retail and e-commerce, crypto, cargo, telecom, and video games industries. Teleperformance SE was incorporated in 1989 and is headquartered in Paris, France.

CAC 40 ended the session with TELEPERFORMANCE sliding 16.13% to €111.80 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.08% to €7,954.39, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, TELEPERFORMANCE has a trailing twelve months EPS of €10.78.

PE Ratio

TELEPERFORMANCE has a trailing twelve months price to earnings ratio of 10.37. Meaning, the purchaser of the share is investing €10.37 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.54%.

Volatility

TELEPERFORMANCE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.01%, a negative 0.52%, and a positive 1.90%.

TELEPERFORMANCE’s highest amplitude of average volatility was 1.26% (last week), 1.24% (last month), and 1.90% (last quarter).

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 21, 2023, the estimated forward annual dividend rate is 3.85 and the estimated forward annual dividend yield is 2.92%.

Yearly Top and Bottom Value

TELEPERFORMANCE’s stock is valued at €111.80 at 21:40 EST, way below its 52-week high of €275.40 and way above its 52-week low of €96.62.

More news about TELEPERFORMANCE.

5. ONWARD MEDICAL (ONWD.BR)

-10.78% Price Change

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

BEL 20 ended the session with ONWARD MEDICAL sliding 10.78% to €4.55 on Wednesday while BEL 20 rose 0.09% to €3,700.02.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.93%.

Yearly Top and Bottom Value

ONWARD MEDICAL’s stock is valued at €4.55 at 21:40 EST, way under its 52-week high of €6.58 and way above its 52-week low of €1.85.

Volatility

ONWARD MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.47%, a positive 4.31%, and a positive 5.79%.

ONWARD MEDICAL’s highest amplitude of average volatility was 2.95% (last week), 10.62% (last month), and 5.79% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL’s stock is considered to be overbought (>=80).

More news about ONWARD MEDICAL.

6. MYHOTELMATCH (MHM.PA)

-10.27% Price Change

MyHotelMatch S.A. engages in the development of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. MyHotelMatch S.A. was incorporated in 2010 and is headquartered in Biot, France.

CAC 40 ended the session with MYHOTELMATCH falling 10.27% to €0.72 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.08% to €7,954.39, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-1.28.

More news about MYHOTELMATCH.

7. MAAT PHARMA (MAAT.PA)

-9.88% Price Change

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

CAC 40 ended the session with MAAT PHARMA falling 9.88% to €7.66 on Wednesday while CAC 40 rose 0.08% to €7,954.39.

Earnings Per Share

As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.4.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.11%.

More news about MAAT PHARMA.

8. AVENIR TELECOM (AVT.PA)

-9.18% Price Change

Avenir Telecom S.A. designs and distributes mobile phones and mobility accessories in Europe, the Middle East, Africa, Asia, Oceania, and the Americas. The company also provides chargers, cables, memory cards, and screen protectors. It offers its products under the Energizer brand. The company was incorporated in 1989 and is headquartered in Marseille, France.

CAC 40 ended the session with AVENIR TELECOM dropping 9.18% to €0.13 on Wednesday, after three sequential sessions in a row of losses. CAC 40 jumped 0.08% to €7,954.39, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, AVENIR TELECOM has a trailing twelve months EPS of €-0.29.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AVENIR TELECOM’s stock is considered to be overbought (>=80).

More news about AVENIR TELECOM.

9. ENSURGE MICROPOWER (ENSU.OL)

-8.72% Price Change

Ensurge Micropower ASA manufactures and sells ultrathin energy storage solutions for wearable devices, connected sensors, and other applications. Its solid-state lithium battery technology enables it to produce rechargeable batteries. The company was formerly known as Thin Film Electronics ASA and changed its name to Ensurge Micropower ASA in June 2021. Ensurge Micropower ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ENSURGE MICROPOWER falling 8.72% to €0.30 on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.3% to €1,263.82, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, ENSURGE MICROPOWER has a trailing twelve months EPS of kr-0.5.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ENSURGE MICROPOWER’s EBITDA is -150.46.

More news about ENSURGE MICROPOWER.

10. GROUPE JAJ (GJAJ.PA)

-8.33% Price Change

Groupe JAJ distributes clothing products. It offers clothing products of the SCHOTT brand. The company was formerly known as JAJ Distribution. The company is headquartered in Montreuil, France.

CAC 40 ended the session with GROUPE JAJ sliding 8.33% to €1.10 on Wednesday, after five successive sessions in a row of losses. CAC 40 rose 0.08% to €7,954.39, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, GROUPE JAJ has a trailing twelve months EPS of €0.15.

PE Ratio

GROUPE JAJ has a trailing twelve months price to earnings ratio of 7.33. Meaning, the purchaser of the share is investing €7.33 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 56.17%.

Volatility

GROUPE JAJ’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.83%, a negative 9.92%, and a positive 11.22%.

GROUPE JAJ’s highest amplitude of average volatility was 0.83% (last week), 9.92% (last month), and 11.22% (last quarter).

More news about GROUPE JAJ.

Stay up to date with our winners and losers daily report